Meta-analysis of the efficacy of a single dose of phenylephrine 10 mg compared with placebo in adults with acute nasal congestion due to the common cold

Clinical Therapeutics

Volumn 29, Issue 6, 2007, Pages 1057-1070

  Kollar, Christine ^a   Schneider, Heinz ^b   Waksman, Joel ^c   Krusinska, Eva ^a  

^a GLAXOSMITHKLINE   (United States)

^b Department of Science and Technology   (United States)

^c PFIZER INC   (United States)

Author keywords

nasal airway resistance; nasal decongestant; nonprescription phenylephrine

Indexed keywords

DECONGESTIVE AGENT; PHENYLEPHRINE; PLACEBO;

ANALYSIS OF COVARIANCE; ARTICLE; CLINICAL TRIAL; COCHRANE LIBRARY; COMMON COLD; DRUG EFFECT; DRUG EFFICACY; FOOD AND DRUG ADMINISTRATION; HUMAN; LITERATURE; MEDLINE; META ANALYSIS; NOSE AIRWAY RESISTANCE; NOSE CONGESTION; PUBLICATION; RANDOMIZATION; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTEMATIC REVIEW;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADULT; COMMON COLD; CROSS-OVER STUDIES; HUMANS; NASAL DECONGESTANTS; NASAL OBSTRUCTION; PHENYLEPHRINE; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME;

EID: 34547589840     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.05.021     Document Type: Article

References (25)

1. Dept of Health and Human Services, Food and Drug Administration. Establishment of a monograph for OTC cold, cough, allergy, bronchodilator and anti-asthmatic products. Fed Regist 41 (1976) 38399-38400
2. Dept of Health and Human Services, Food and Drug Administration. Cold, cough, allergy, bronchodilator and anti-asthmatic drug products for over-the-counter human use; final monograph for OTC nasal decongestant drug products. Fed Regist 59 (1994) 43386-43412
3. Hendeles L., and Hatton R. Oral phenylephrine: An ineffective replacement for pseudoephedrine?. J Allergy Clin Immunol 118 (2006) 279-280
4. CD001953. Taverner D., Latte J., and Draper M. Nasal decongestants for the common cold. Cochrane Database Syst Rev 3 (2004)
5. Hutton N., Wilson M., Mellits E., et al. Effectiveness of an antihistamine-decongestant combination for young children with the common cold: A randomized, controlled clinical trial. J Pediatr 118 (1991) 125-130
6. Cohen B. Clinical and physiological "significance" of drug-induced changes in nasal flow/resistance. Eur J Clin Pharmacol 5 (1972) 81-86
7. Whitehead A. Meta-Analysis of Controlled Clinical Trials (2002), John Wiley & Sons, Chichester, UK
8. Senn S. The many modes of meta. Drug Info J 34 (2000) 535-549
9. DerSimonian R., and Laird N. Meta-analysis in clinical trials. Control Clin Trials 7 (1986) 177-188
10. January. Memo to Wessinger from NA Hulme. Nasal decongestant study by Elizabeth Biochemical No. 2. FDA OTC Volume 040298 (1968)
11. May. Memo to Blackmore from NA Hulme. Neo-Synephrine-Elizabeth Biochemical Laboratory Study No. 5. FDA OTC Volume 040298 (1970)
12. May. Memo to Blackmore from NA Hulme. Oral Neo-Synephrine-Cintest Labs Study No. 1. FDA OTC Volume 040298 (1969)
13. January. Memo to Blackmore from NA Hulme. Oral Neo-Synephrine-Cintest Labs Study No 2. FDAOTC Volume 040298 (1970)
14. May. Memo to Blackmore from NA Hulme. Oral Neo-Synephrine-Cintest Labs Study No 3. FDA OTC Volume 040298 (1970)
15. May. Memo to Blackmore from NA Hulme. Oral Neo-Synephrine-Huntingdon Research Center Study No 1. FDA OTC Volume 040298 (1969)
16. January. Memo to Blackmore from NA Hulme. Oral Neo-Synephrine-Huntingdon Research Center Study No 2. FDA OTC Volume 040298 (1970)
17. June. Cohen B. Objective and subjective evaluation of phenylephrine HCI (5 mg) versus placebo tablets. FDA OTC Volume 04088B (1975)
18. April 23. Memo to Lands from FP Luduena. Comparative study of the effects of Neo-synephrine HCI and Propadrine HCI on nasal air resistance (NAR), blood pressure and pulse rate of volunteers. FDA OTC Volume 040298 (1959)
19. June. Memo to Suter from NA Hulme. Nasal Decongestant Study by Elizabeth Biochemical Laboratories No 1. FDA OTC Volume 040298 (1967)
20. June. Memo to Blackmore from NA Hulme. Oral Neo-Synephrine-Elizabeth BioChemical Study No 3. FDA OTC Volume 040298 (1969)
21. August. Memo to Blackmore from NA Hulme. Oral Neo-Synephrine-Elizabeth Biochemical Study No 4. FDA OTC Volume 040298 (1969)
22. McLaurin J., Shipman W., and Rosedale Jr. R. Oral decongestants. A double blind comparison study of the effectiveness of four sympathomimetic drugs: Objective and subjective. Laryngoscope 71 (1961) 54-67
23. N). Current Research Methodology in the Evaluation of Proprietary Medicines: Proceedings of a Conference Sponsored by the Scientific Development Committee of the Proprietary Association (1971), The Proprietary Association, New York, NY 61-72
24. April. US Dept of Health and Human Services, Food and Drug Administration, and Center for Drug Evaluation and Research. Guidance for industry. Allergic rhinitis: Clinical development programs for drug products. Available at http://www.fda.gov/CDER/guidance/2718dft.pdf. Accessed October 16, 2006. (2000)
25. Morishita H., and Furukawa T. The vascular changes after ephedrine tachyphylaxis. J Pharm Pharmacol 27 (1975) 574-579